$2,376.83 general Payment -- Pfizer Inc to Dr. Paul Turner
Pfizer Inc. Pays $2,376.83 to Internal Medicine Physician for Mounjaro Education
This page provides a detailed analysis of a $2,376.83 general payment from Pfizer Inc to Dr. Paul Turner. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $2,376.83 |
| Payment Type | general |
| Payment Nature | Education |
| Pharmaceutical Company | Pfizer Inc |
| Physician | Dr. Paul Turner |
| NPI Number | 1778137407 |
| Physician Specialty | Internal Medicine |
| Location | Akron, OH |
| Date of Payment | 2024-08-09 |
| Related Drug/Device | Mounjaro |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Pfizer Inc made a $2.4K general payment to Paul Turner, a Internal Medicine specialist in Akron, OH. The payment was associated with Mounjaro. The payment of $2,376.83 to Dr. Paul Turner for "Education" related to Mounjaro is a significant amount for a single educational event. Pfizer Inc. made this payment, indicating a direct relationship between the pharmaceutical company and the physician for product promotion or education. The payment occurred on August 9, 2024, suggesting a recent engagement between the pharma company and the physician.
Patient Guidance: What This Payment Means for You
Patients should be aware that their physicians may receive payments from pharmaceutical companies for educational purposes related to specific medications. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for educational purposes to Internal Medicine physicians can vary widely, but this amount for a single educational event is on the moderate side compared to some other payment types.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act's reporting requirements, which mandate disclosure of payments made by drug and device manufacturers to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- drug-education
- open-payments
- internal-medicine
- mounjaro
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $2.4K payment for?
This was a general payment of $2.4K from Pfizer Inc to Paul Turner, categorized as "Education". It was associated with Mounjaro. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Paul Turner accept pharmaceutical money?
Yes, Paul Turner received this $2.4K payment from Pfizer Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Paul Turner's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $2.4K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Internal Medicine?
To compare this payment against Internal Medicine averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Internal Medicine physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Paul Turner's relationship with Pfizer Inc?
The payment nature is categorized as 'Education', which is a common but sometimes scrutinized aspect of pharma-physician interactions. This $2.4K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Internal Medicine?
The specific drug mentioned is Mounjaro, a medication often associated with significant marketing and educational efforts by its manufacturer.
What should patients do after learning about this payment?
Patients should be aware that their physicians may receive payments from pharmaceutical companies for educational purposes related to specific medications.
What else should I know about this general payment?
Dr. Paul Turner, an Internal Medicine specialist, received this payment, placing the interaction within a common specialty for such payments.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.